All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
EquityFollow-ons and Rights issues

Solvay plans €1.5bn rights issue to fund Cytec takeover

chemicals_230px

Solvay, the Belgian chemicals company, is buying Cytec in a deal that values the US-based firm at $6.4bn and will be funded in part by a rights issue.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree